- Analgesia in the ICU
- Bacterial Infections
- Fungal Infections
- Infection Control and Prevention
- Mechanical Ventilation
- Viral Infections
Webcasts
- Complicated UTI & Urosepsis: Uro- Physician Perspectives
- Role of Fosfomycin IV in VAP, Sepsis and Bacterial Meningitis Patients
- CLSI 2020 Updates
- Dealing with Complicated UTI to Urosepsis in the era of Antibiotic Resistance: Case based Discussion on role of Ceftriaxone Sulbactam EDTA
- The Fine Line: Role of Fosfomycin IV in VAP and Sepsis Patients
- Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?
- Strengthening the Wall: Role of Sulbactam and Colistin in MDR Gram-Negative Infections
- Time Series Analysis of Antibiotic Resistance at a Tertiary Care Hospital & Community in Delhi
- Minocycline IV for the Treatment of MDR/ XDR Bacterial Infections
- Colistin in Carbapenem Resistant Infections Experience from an Indian Centre
- Aerolized Antibiotics and VAP
- Role of I.V. Fosfomycin in the Management of MDR/XDR Infections
- Fosfomycin - Exploring the Therapeutic Value
- CarbapenemAce - A New Look at Carbapenems in 2014
- My Antibiotic Partner for Colistin
- Strengthening the Wall: Colistin for Tomorrow
- Therapeutic Drug Monitoring of Anti-Infectives in the ICU: The Way Forward
- Aerosolized Antibiotics: To Administer or Not?
- Colistin: Yesterday, Today and Tomorrow
- If the Last Wall Falls…..The Need for Optimal use of Colistin
- Optimizing the Use of Colistin in MDR Infections
Expert's Viewpoint
- Experience sharing on Dose optimization of Minocycline Injection
- 3 reasons to Optimize the Dose of Minocycline
- Management of Complicated UTI – A Case Discussion (Case 2)
- Management of Complicated UTI – A Case Discussion (Case 3)
- Experience Sharing of High Dose Minocycline by Infectious Disease Specialist
- Management of Complicated UTI – A Case Discussion
- Webinar Snippet: Can Minocycline be Used Against CRE and at What Dose?
- Webinar Snippet: Can Minocycline be Given as a Monotherapy?
- Webinar Snippet: Is Minocycline Safe to Use?
- Webinar Snippet: Does Minocycline Score Over Colistin?
- Webinar Snippet: Why Tigecycline Not Recommended in Blood Stream Infection?
- Webinar Snippet: Why High Dose Minocycline Should be Used?
Our Publications
- Clarithromycin: An Emerging Treatment Recourse in Lower Respiratory Tract Infections
- MRSA: The Clinician’s Challenge
- ABC of Anti-infectives : A Handbook on Anti-infective Armamentarium
- Sulbacip (Sulbactam) I.V. Monograph
- Antimicrobial Spectrum Reckoner
- Vanlid (Vancomycin) Monograph
- Xylistin (Colistimethate Sodium) Monograph
- Cellulitis/Erysipelas
- Necrotizing Fasciitis
- Pocket Guide For Antimicrobial Dosing In Renal Failure
- CA-MRSA
- Stenotrophomonas maltophilia
- Pathopedia of Acinetobacter
- Extended Spectrum Beta Lactamases (ESBLs): Incidence and Susceptibility in India
- Interrelationship Between Dose, Pharmacokinetics (Concentration), Pharmacodynamics and Clinical Effects
- Pseudomonas: Incidence and Susceptibility in India
Key Trials
- Ceftriaxone, Sulbactam and Disodium EDTA Combination Effective Against E. coli Infections
- Recurrent Pseudomonas aeruginosa Infections after Allogenic Hematopoietic Cell Transplantation
- Ceftriaxone, Sulbactam and Disodium EDTA Combination Therapy Might Spare Carbapenems in Management of Multidrug Resistant Nosocomial Infections
- Noninferiority of Ceftriaxone, Sulbactam, and Disodium EDTA to Meropenem in Complicated UTIs
- Indian Prospective Study Comparing the Nephrotoxicity of Colistin and Polymyxin B Administered in Currently Recommended Doses
- BLISS Study: Continuous Administration of Beta-lactams Associated with Higher Clinical Cure Rates and Better PK/PD Target Attainment Compared to Intermittent Bolus Dosing
Conference Proceedings
Clinical Tools
Guidelines
- IDSA: Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children (2011)
- Surgical Infection Society & IDSA: Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children (2010)
- IDSA: Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults (2009)
- ATS & IDSA: Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia (2005)
Webcasts
- Art of Prescribing Antifungals
- Place in Therapy Of I.V Posaconzole In the Management of Invasive fungal infections in High-Risk Patients
- Dilemmas in the Management of Invasive Aspergillosis
- Empiric Therapy for Invasive Fungal Infections
- How Do I Treat Candida and Aspergillosis in the ICU
- Emerging Fungi in The ICU
- Prevalence, Diagnosis and Management of Differential Fungal Infections
- Update on Invasive Fungal Infections
- The 4 W’s of Antifungals: Why, Whom, Which and When
Our Publications
- Phosome IV (Liposomal Amphotericin B) Monograph
- Antimicrobial Spectrum Reckoner
- Caspogin I.V. (Caspofungin acetate) Data Sheet
- The Action of Phosome (Liposomal Amphotericin B)
- The Challenge of Creating Liposomal Amphotericin B
- The Search for a Magic Bullet
- Pocket Guide For Antimicrobial Dosing In Renal Failure
Conference Proceedings
Clinical Tools
Webcasts
Key Trials
Conference Proceedings
Clinical Tools
Conference Proceedings
Guidelines
- ATS/ACCP: Liberation from Mechanical Ventilation in Critically Ill Adults (2016)
- AARC Expert Panel Reference-Based Guidelines: Capnography/Capnometry during Mechanical Ventilation (2011)
- AARC Evidence-Based Clinical Practice Guidelines: Care of the Ventilator Circuit and Its Relation to Ventilator-Associated Pneumonia (2003)
Our Publications
Key Trials
- Does Remdesivir Provide a Benefit on Clinical Status for Patients Hospitalized with Moderate COVID-19 Pneumonia?
- Remdesivir Improves Survival Outcomes in ICU Patients with COVID-19 under Mechanical Ventilation
- Efficacy and Safety of Remdesivir 5 Days Course verses 10 Days Course in Treatment of Patients with Severe Covid-19 Disease
- Remdesivir Shortens Time to Recovery in Patients Hospitalized with COVID-19
- Compassionate Use of Remdesivir to Treat Patients with Severe Covid-19
- Early Intervention with Remdesivir Associated with Clinical Improvement in Severe COVID-19 Patients
